Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

Bullboard (OTCPK:ARLZQ)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by snootchybootchyon Mar 27, 2017 5:39pm

RE:RE:Another Seeking Alpha article

Yes, a flop in Zontivity would change the story in my mind, because that would also likely affect Yosprala sales.  But again, if uptake of Zontivity is slow a few months after the launch, I would ...more  
167
Discussion
Comment by GoldenDilemmaon Mar 27, 2017 3:01pm

RE:Another Seeking Alpha article

When does the story change in your mind? A Zontivity flop? Lackluster Yosprala sales?  And, to add, post earnings drop is a micro perspective ignoring the macro perspective of the downward slope ...more  
80
Discussion
Post by snootchybootchyon Mar 27, 2017 2:39pm

Another Seeking Alpha article

Mr. Goldman has been busy working on this T.ARZ.  The new article summarizes his interview with Mr. Adams and he also provides some updated thoughts on the prospects of Aralez going forward ...more  
164
Discussion
Comment by kuatoliveson Mar 26, 2017 12:34pm

RE:Interview with Adrian Adams

Don't listen to this dog and pony show. After wiping out Tribute shareholders, Mr. Goldman sold half his stake in Aralez just recently, so his actions don't reflect the 'confidence' he ...more  
133
Discussion
Post by snootchybootchyon Mar 25, 2017 3:45pm

Interview with Adrian Adams

There is an interview with Mr. Adams posted up on Seeking Alpha.  One can see why Mr. Adams is still optimistic -- he thinks there is lots of potential with Zontivity and he also believes that ...more  
217
Discussion
Comment by Systemtogoon Mar 22, 2017 11:00pm

RE:RE:PPI May Cause Kidney Damage

I know people that have been on ppi's for many years and don't have kidney issues. If you have serious gastritis and GERD then you need them. Two in one, Naproxen with PPI's are a common ...more  
104
Discussion
Comment by CHECKMATE77on Mar 22, 2017 4:28pm

RE:PPI May Cause Kidney Damage

i am in healthcare, ppi have a number of issues not just the above but they also 1- prevent to a degree gastric perferation 2- improve quality of life hell asa has issues...name a drug that does not  ...more  
100
Discussion
Post by kuatoliveson Mar 22, 2017 3:03pm

PPI May Cause Kidney Damage

Another risk: https://www.cbc.ca/news/health/heartburn-drugs-kidney-damage-1.3994789
102
Discussion
Comment by GoldenDilemmaon Mar 21, 2017 11:51am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely

Please point me in the direction of where I said that...? ARLZ has a lot more to do with earnings. In fact, based on earnings, they did well in the past Q. Doesn't matter, though. 
97
Discussion
Comment by Systemtogoon Mar 21, 2017 11:50am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely

So you buy your stocks based on earnings? Good luck with that. I always go against the sheep. 
86
Discussion
Comment by GoldenDilemmaon Mar 21, 2017 11:31am

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely

Sorry, should have clarified, the former (ARLZ), is specialty pharma. A well loved entity within the bio sector, especially if they take on debt to sell drugs (and, even more love if those drugs face ...more  
84
Discussion
Comment by GoldenDilemmaon Mar 21, 2017 11:29am

RE:RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely

No comparison between ARLZ and AUP. The latter does R&D. The former has debt and a drug portfolio shorts deem worthless. But, again, fundamentals don't matter, right?  ARLZ market cap ...more  
83
Discussion
Post by Systemtogoon Mar 21, 2017 11:29am

Yosprala prospects

I think this drug is way undervalued. Think of how many elderly people there are that need aspirin and have acid reflux. It has brilliant mass market appeal. A good management team should be able to ...more  
96
Comment by Systemtogoon Mar 21, 2017 11:01am

RE:RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely

Management weren't buying all the way. You can refer to the following chart to see when they bought. I'm not basing my philosophy on ARZ, I'm basing on every pick I see that follows this ...more  
108
Discussion
Comment by Systemtogoon Mar 21, 2017 10:53am

RE:RE:RE:RE:RE:RE:RE:Picks like ARZ come around very rarely

For someone who misunderstands it's unbelievable how many times I'm right. It's actually the only system worth a damm in trading. 
85
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities